5MeCDDO blocks metabolic activation but not progression of breast, intestine, and tongue cancers. Is antioxidant response element a prevention target?

Keyphrases

• Breast Cancer 100%
• Head-and-neck Cancer 100%
• Intestinal Cancer 100%
• GSTP1 100%
• Antioxidant Response Element 100%
• Intestine Tumor 100%
• Tongue Cancer 100%
• Quinone Reductase 100%
• Metabolic Activation 100%
• Mammary Cancer 100%
• Liver 50%
• Mouse Model 50%
• High Dose 50%
• Sprague-Dawley Rats 50%
• Cancer Model 50%
• Tumor multiplicity 50%
• Soluble Epoxide Hydrolase 50%
• Adenoma 50%
• Tumor Incidence 50%
• Tumor Invasiveness 50%
• Procarcinogen 50%
• Carcinogen Activation 50%
• Min Mice 50%
• Nitroquinolines 50%
• Phase II Enzymes 50%
• Triterpenoids 50%
• Ah Receptor 50%
• Chemopreventive 50%
• Preventive Efficacy 50%
• Dimethylbenzanthracene 50%
• Receptor Agonist 50%
• Benzoflavone 50%
• Oxides 50%
• Chemically Induced Models 50%
• Aflatoxicol 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Intestine Cancer 100%
• Antioxidant 100%
• Tongue Cancer 100%
• Reduced Nicotinamide Adenine Dinucleotide (Phosphate) Dehydrogenase (Quinone) 66%
• Head and Neck Cancer 66%
• Neoplasm 33%
• Malignant Neoplasm 33%
• Mouse Model 33%
• Cancer Incidence 33%
• Carcinogen 33%
• Drug Metabolizing Enzyme 33%
• Nitroquinoline Derivative 33%
• Receptor Agonist 33%
• Epoxide Hydrolase 33%
• Dimethylbenz[a]anthracene 33%
• Aflatoxicol 33%
• Beta-Naphthoflavone 33%
• Adenoma 33%
• Cancer Model 33%
• Sprague Dawley Rat 33%
• Triterpenoid 33%
• Aromatic Hydrocarbon Receptor 33%